Application_NN of_IN Real-Time_NP PCR_NP for_IN Determination_NP of_IN Antiviral_JJ Drug_NP Susceptibility_NP of_IN Herpes_NP Simplex_NP Virus_NP A_DT quantitative_JJ real-time_JJ PCR_NP (_( TaqMan_NP )_) assay_NN was_VBD developed_VBN for_IN determination_NN of_IN antiviral_JJ drug_NN susceptibility_NN of_IN herpes_NN simplex_JJ virus_NN (_( HSV_NP )_) ._SENT After_IN short-time_JJ culture_NN of_IN the_DT virus_NN ,_, the_DT antiviral_JJ drug_NN susceptibility_NN of_IN HSV_NP isolates_VBZ for_IN acyclovir_NN (_( ACV_NP )_) was_VBD determined_VBN by_IN measuring_VBG the_DT reduction_NN of_IN the_DT HSV_NP type_NN 1_CD (_( HSV-1_NP )_) DNA_NN levels_NNS in_IN culture_NN supernatants_NNS using_VBG real-time_JJ PCR_NP ._SENT The_DT 50_CD %_NN inhibitory_JJ concentration_NN was_VBD reported_VBN as_IN the_DT concentration_NN of_IN antiviral_JJ drug_NN that_WDT reduced_VBD the_DT number_NN of_IN HSV-1_NP DNA_NP copies_NNS by_IN 50_CD %_NN ._SENT A_DT total_NN of_IN 15_CD well-characterized_JJ ACV-sensitive_JJ or_CC -resistant_JJ strains_NNS and_CC clinical_JJ isolates_NNS were_VBD used_VBN for_IN assay_NN evaluation_NN ._SENT The_DT new_JJ assay_NN with_IN real-time_JJ PCR_NP readout_NN permitted_VBD rapid_JJ (_( 3_CD days_NNS )_) ,_, objective_NN ,_, and_CC reproducible_JJ determination_NN of_IN HSV-1_JJ drug_NN susceptibilities_NNS with_IN no_DT need_NN for_IN stringent_JJ control_NN of_IN initial_JJ multiplicity_NN of_IN infection_NN ._SENT Furthermore_RB ,_, the_DT real-time_JJ PCR_NP assay_NN results_NNS showed_VBD good_JJ correlation_NN (_( r_LS =_SYM 0.86_CD )_) with_IN those_DT for_IN the_DT plaque_NN reduction_NN assay_NN ._SENT In_IN conclusion_NN ,_, the_DT real-time_JJ PCR_NP assay_NN described_VBD here_RB is_VBZ a_DT suitable_JJ quantitative_JJ method_NN for_IN determination_NN of_IN antiviral_JJ susceptibility_NN of_IN HSV-1_NP ,_, amenable_JJ for_IN use_NN in_IN the_DT routine_JJ diagnostic_JJ virology_NN laboratory_NN ._SENT Extensive_JJ use_NN of_IN acyclovir_NN and_CC other_JJ antiviral_JJ drugs_NNS for_IN prophylaxis_NN and_CC treatment_NN of_IN herpes_NN simplex_JJ virus_NN (_( HSV_NP )_) infections_NNS exerts_VBZ a_DT continuous_JJ selection_NN pressure_NN on_IN the_DT HSV_NP virus_NN population_NN ._SENT HSV_NP antiviral_JJ drug_NN resistance_NN occurs_VBZ relatively_RB frequently_RB especially_RB in_IN immunocompromised_JJ patients_NNS such_JJ as_IN those_DT undergoing_VBG bone_NN marrow_NN (_( 6_CD to_TO 12_CD %_NN )_) or_CC solid_JJ organ_NN transplantation_NN (_( similar4_JJ %_NN )_) or_CC AIDS_NP patients_NNS (_( similar6_JJ %_NN )_) and_CC can_MD be_VB associated_VBN with_IN serious_JJ disease_NN (_( ;_: B._NP Lina_NP ,_, D._NP Thouvenot_NP ,_, C._NP Danve_NP ,_, F._NP Morfin_NP ,_, A._NP Boucher_NP ,_, I._NP Berlin_NP ,_, and_CC M._NP Aymard_NP ,_, abstract_JJ from_IN European_JJ Virology_NP 2000_CD ,_, J._NP Clin_NP ._SENT Virol_NP ._SENT 18:47_CD ,_, 2000_CD )_) ._SENT The_DT frequency_NN of_IN HSV-resistant_JJ infections_NNS may_MD increase_VB because_IN of_IN the_DT increasing_VBG number_NN of_IN severely_RB immunocompromised_VBN patients_NNS with_IN chronic_JJ or_CC recurrent_JJ HSV_NP infections_NNS who_WP require_VBP prolonged_JJ administration_NN of_IN antiviral_JJ drugs_NNS ._SENT In_IN this_DT patient_JJ group_NN susceptibility_NN testing_NN is_VBZ needed_VBN to_TO detect_VB drug-resistant_JJ HSV_NP strains_NNS and_CC to_TO reconsider_VB the_DT antiviral_JJ treatment_NN (_( ;_: F._NP Morfin_NP ,_, D._NP Thouvenot_NP ,_, G._NP Souillet_NP ,_, M._NP Michallet_NP ,_, and_CC M._NP Aymard_NP ,_, abstract_JJ from_IN Progress_NP in_IN Clinical_NP Virology_NP V_CD ,_, Acta_NP Microbiol_NP Immunol_NP Hung_NP ._SENT 46:429_CD ,_, 1999_CD )_) ._SENT Safrin_NP et_FW al._FW has_VBZ shown_VBN a_DT good_JJ correlation_NN between_IN the_DT failure_NN of_IN HSV_NP suppression_NN by_IN acyclovir_NN (_( ACV_NP )_) in_IN vivo_JJ and_CC the_DT determination_NN of_IN ACV_NP resistance_NN in_IN vitro_NN ._SENT These_DT observations_NNS emphasized_VBD the_DT clinical_JJ relevance_NN of_IN antiviral_JJ resistance_NN determination_NN in_IN the_DT laboratory_NN ._SENT Several_JJ phenotypic_JJ assays_NNS have_VBP been_VBN described_VBN ,_, and_CC some_DT of_IN them_PP are_VBP used_VBN in_IN clinical_JJ practice_NN ,_, with_IN the_DT plaque_NN reduction_NN assay_NN (_( PRA_NP )_) as_IN the_DT most_RBS frequently_RB used_VBN drug_NN susceptibility_NN assay_NN ._SENT Although_IN this_DT technique_NN is_VBZ laborious_JJ and_CC time-consuming_JJ ,_, it_PP still_RB remains_VBZ the_DT "_`` gold_JJ standard_NN "_'' method_NN by_IN which_WDT other_JJ tests_NNS are_VBP evaluated_VBN ._SENT The_DT majority_NN of_IN alternative_JJ susceptibility_NN assays_NNS is_VBZ based_VBN on_IN reduction_NN in_IN cytopathic_JJ effect_NN (_( CPE_NP )_) ,_, which_WDT is_VBZ either_RB microscopically_RB evaluated_VBN or_CC colorimetrically_RB detected_VBN ._SENT Assays_NNS based_VBN on_IN enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) include_VBP the_DT sandwich_NN ELISA_NP and_CC the_DT microplate_NN in-situ_NN ELISA_NP (_( MISE-test_NN )_) ._SENT The_DT latter_NN has_VBZ been_VBN shown_VBN to_TO correlate_VB well_RB with_IN PRA_NP ._SENT Other_JJ currently_RB used_VBN antiviral_JJ susceptibility_NN assays_NNS involve_VBP the_DT use_NN of_IN DNA_NN hybridization_NN ,_, flow_NN cytometric_JJ analysis_NN and_CC transgenic_JJ HSV_NP inducible_JJ reporter_NN cells_NNS ._SENT With_IN the_DT increasing_VBG numbers_NNS of_IN immunocompromised_JJ individuals_NNS ,_, there_EX is_VBZ a_DT need_NN for_IN the_DT widespread_JJ routine_JJ availability_NN of_IN antiviral_JJ drug_NN susceptibility_NN assays_NNS ,_, which_WDT would_MD be_VB rapid_JJ ,_, reproducible_JJ and_CC clinically_RB relevant_JJ ._SENT Currently_RB used_VBN methods_NNS ,_, except_IN for_IN the_DT MISE-test_NN ,_, suffer_VBP from_IN certain_JJ pitfalls_NNS ,_, which_WDT preclude_VBP their_PP$ routine_JJ use_NN ._SENT Most_JJS of_IN the_DT assays_NNS are_VBP time-consuming_JJ and_CC labor-intensive_JJ ;_: some_DT may_MD have_VB subjective_JJ endpoints_NNS ,_, require_VBP special_JJ equipment_NN or_CC trained_JJ laboratory_NN personnel_NNS ._SENT Therefore_RB we_PP set_VBD out_RP to_TO develop_VB an_DT assay_NN ,_, which_WDT would_MD overcome_VB most_JJS of_IN the_DT aforementioned_JJ restrictions_NNS and_CC could_MD be_VB easily_RB implemented_VBN in_IN the_DT diagnostic_JJ laboratory_NN ._SENT We_PP describe_VBP the_DT development_NN and_CC evaluation_NN of_IN a_DT new_JJ approach_NN for_IN HSV-1_JJ drug_NN susceptibility_NN determination_NN using_VBG quantitative_JJ real-time_JJ PCR_NP (_( TaqMan_NP )_) to_TO measure_VB viral_JJ DNA_NN production_NN ._SENT Cells_NNS and_CC viruses_NNS ._SENT |_SYM Vero_NP cells_NNS (_( African_JJ green_JJ monkey_NN kidney_NN )_) were_VBD propagated_VBN and_CC maintained_VBN in_IN Iscove_NP 's_POS modified_JJ Dulbecco_NP 's_POS medium_NN (_( Life_NP Technologies_NP ,_, Breda_NP ,_, The_DT Netherlands_NPS )_) supplemented_VBD with_IN 5_CD %_NN fetal_JJ bovine_JJ serum_NN and_CC gentamicin_NN (_( 10_CD mug/ml_NN ;_: Life_NP Technologies_NPS ,_, Breda_NP ,_, The_DT Netherlands_NPS )_) ._SENT A_DT stock_NN of_IN HSV-1_NP strain_NN McIntyre_NP counted_VBN by_IN electron_NN microscopy_NN (_( EM_NP )_) was_VBD obtained_VBN from_IN Advanced_NP Biotechnologies_NP ._SENT Inc._NP ,_, Columbia_NP ,_, Md._NP The_NP HSV-1_NP strain_NN KOS_NP and_CC the_DT KOS-derived_NP ACV-resistant_NP mutants_NNS (_( AraAr7_NP ,_, AraAr8_NP ,_, AraAr13_NP ,_, F891C_NP ,_, PFAr5_NP ,_, and_CC PAAr5_NP )_) were_VBD kindly_RB provided_VBN by_IN D._NP M._NP Coen_NP (_( Harvard_NP Medical_NP School_NP ,_, Boston_NP ,_, Mass._NP )_) ._SENT The_DT HSV-1_NP ACV-sensitive_NP strains_NNS McIntyre_NP and_CC R39_NP were_VBD generously_RB provided_VBN by_IN A._NP Linde_NP (_( Swedish_NP Institute_NP for_IN Infectious_NP Disease_NP Control_NP ,_, Solna_NP ,_, Sweden_NP )_) ._SENT Well-characterized_JJ ACV-resistant_JJ clinical_JJ isolates_NNS HSV_NP 98.25733-MA/3_NP ,_, HSV_NP 98.15779-VA/2_NP and_CC HSV_NP 98.14742-PE/1_NP (_( Morfin_NP et_FW al._FW ,_, Acta_NP Microbiol_NP Immunol_NP Hung_NP ._SENT 46:429_CD ,_, 1999_CD )_) were_VBD a_DT gift_NN of_IN M._NP Aymard_NP (_( Universite_NP Claude_NP Bernard_NP ,_, Lyon_NP ,_, France_NP )_) ._SENT Other_JJ HSV-1_JJ clinical_JJ isolates_NNS were_VBD selected_VBN from_IN our_PP$ own_JJ collection_NN ;_: two_CD originated_VBN from_IN patients_NNS after_IN bone_NN marrow_NN transplantation_NN who_WP had_VBD recurrent_JJ HSV_NP infections_NNS not_RB responding_VBG to_TO ACV_NP ,_, and_CC one_CD was_VBD obtained_VBN from_IN a_DT patient_NN with_IN oral_JJ HSV_NP infection_NN which_WDT resolved_VBD spontaneously_RB ._SENT Virus_NN stocks_NNS were_VBD grown_VBN in_IN Vero_NP cells_NNS and_CC the_DT infectious_JJ titer_NN was_VBD determined_VBN by_IN plaque_NN assay_NN in_IN Vero_NP cells_NNS as_IN previously_RB described_VBN by_IN Schaffer_NP et_FW al._FW ._SENT Real-time_JJ PCR_NP assay_NN for_IN HSV-1_NP :_: assay_NN setup_NN ._SENT |_SYM HSV-1-specific_NP PCR_NP primers_NNS and_CC a_DT fluorescent_JJ probe_NN directed_VBN to_TO the_DT HSV-1_NP glycoprotein_NN G_NP (_( gG_NN )_) gene_NN were_VBD used_VBN for_IN real-time_JJ PCR_NP analysis_NN as_IN described_VBN by_IN Ryncarz_NP et_FW al._FW ._SENT Each_DT 25_CD mul_NN of_IN PCR_NP mixture_NN contained_VBD 7_CD mul_NN of_IN a_DT 1:100-diluted_JJ culture_NN supernatant_JJ ,_, 900_CD nM_NN concentrations_NNS of_IN both_DT forward_JJ and_CC reverse_JJ primer_NN ,_, and_CC 150_CD nM_NN probe_NN ._SENT Amplification_NN was_VBD performed_VBN using_VBG the_DT Applied_NP Biosystems_NP Sequence_NP Detector_NP 7700_CD under_IN the_DT following_VBG conditions_NNS :_: incubation_NN for_IN 2_CD min_NN at_IN 50C_NN ,_, and_CC then_RB for_IN 10_CD min_NN at_IN 95C_NN ,_, followed_VBN by_IN 45_CD cycles_NNS of_IN 15_CD s_NNS at_IN 95C_NN and_CC 1_CD min_NN at_IN 60C_JJ ._SENT Each_DT PCR_NP run_NN contained_VBD two_CD negative_JJ controls_NNS and_CC a_DT dilution_NN series_NN of_IN HSV-1_NP DNA_NP (_( 6_CD x_SYM 102_CD to_TO 6_CD x_SYM 108_CD copies/ml_NN )_) derived_VBN from_IN EM-counted_JJ virus_NN stock_NN (_( HSV-1_NP ,_, McIntyre_NP )_) ,_, which_WDT was_VBD used_VBN to_TO generate_VB the_DT standard_JJ curve_NN ._SENT Each_DT sample_NN was_VBD analyzed_VBN in_IN duplicate_NN ._SENT Assay_NN optimization_NN ._SENT |_SYM The_DT kinetics_NN of_IN HSV-1_NP DNA_NP replication_NN was_VBD examined_VBN by_IN measuring_VBG the_DT time_NN course_NN of_IN increase_NN in_IN HSV-1_NP DNA_NP yield_NN in_IN cell_NN culture_NN supernatants_NNS ._SENT Vero_NP cells_NNS in_IN 24-well_JJ culture_NN plates_NNS were_VBD infected_VBN at_IN a_DT multiplicity_NN of_IN infection_NN (_( MOI_NP )_) of_IN 0.1_CD ,_, 0.01_CD ,_, and_CC 0.001_CD PFU/cell_NP of_IN HSV-1_NP strain_NN McIntyre_NP ._SENT The_DT development_NN of_IN CPE_NP was_VBD monitored_VBN ,_, and_CC the_DT levels_NNS of_IN HSV-1_NP DNA_NP were_VBD measured_VBN by_IN real-time_JJ PCR_NP in_IN supernatant_JJ samples_NNS collected_VBN at_IN 12-h_NP intervals_NNS after_IN infection_NN ._SENT Experiments_NNS were_VBD also_RB performed_VBN to_TO evaluate_VB the_DT effect_NN of_IN ACV_NP in_IN the_DT cell_NN culture_NN supernatant_JJ on_IN PCR_NP efficiency_NN ._SENT Virus_NN infected_VBD cell_NN cultures_NNS (_( MOI_NP ,_, 0.01_CD )_) were_VBD incubated_VBN with_IN or_CC without_IN a_DT high_JJ concentration_NN of_IN ACV_NP (_( 48_CD mug/ml_NN )_) for_IN 48_CD h_NN to_TO resemble_VB the_DT conditions_NNS of_IN the_DT assay_NN described_VBD here_RB ._SENT Subsequently_RB cell_NN culture_NN supernatants_NNS were_VBD collected_VBN and_CC spiked_VBN with_IN HSV-1_NP DNA_NP ._SENT These_DT spiked_JJ samples_NNS were_VBD amplified_VBN using_VBG the_DT real-time_JJ PCR_NP assay_NN ,_, either_CC as_IN undiluted_JJ supernatant_JJ or_CC as_IN a_DT dilution_NN series_NN ._SENT The_DT effect_NN of_IN the_DT MOI_NP on_IN the_DT ACV_NP IC50s_NP was_VBD determined_VBN in_IN parallel_JJ experiments_NNS in_IN which_WDT cell_NN cultures_NNS were_VBD infected_VBN with_IN a_DT half-log10_JJ incremental_JJ range_NN of_IN infectious_JJ doses_NNS (_( MOI_NP ,_, 0.001_CD to_TO 0.5_CD PFU/cell_NN )_) of_IN HSV-1_NP in_IN the_DT presence_NN of_IN serial_JJ concentrations_NNS of_IN ACV_NP ._SENT The_DT levels_NNS of_IN HSV-1_NP DNA_NP were_VBD measured_VBN by_IN real-time_JJ PCR_NP in_IN supernatant_JJ samples_NNS collected_VBN at_IN 24_CD ,_, 48_CD ,_, and_CC 72_CD h_NN postinfection_NN ,_, and_CC the_DT 50_CD %_NN inhibitory_JJ concentrations_NNS (_( IC50s_NP )_) were_VBD determined_VBN ._SENT The_DT CPE_NN of_IN the_DT virus_NN control_NN was_VBD scored_VBN at_IN the_DT time_NN of_IN supernatant_JJ collection_NN ._SENT Real-time_JJ PCR_NP assay_NN for_IN HSV-1_JJ antiviral_JJ susceptibility_NN testing_NN :_: final_JJ setup_NN ._SENT |_SYM Virus_NP isolates_NNS at_IN an_DT MOI_NP of_IN 0.01_CD (_( 50_CD mul_NN )_) were_VBD dispensed_VBN in_IN duplicate_NN into_IN wells_NNS of_IN the_DT 24-well_JJ culture_NN plate_NN containing_VBG 450_CD mul_NN of_IN culture_NN medium_NN with_IN different_JJ concentrations_NNS of_IN ACV_NP and_CC a_DT suspension_NN of_IN Vero_NP cells_NNS (_( 6_CD x_SYM 105_CD cells/ml_NN )_) ._SENT Serial_JJ twofold_JJ dilutions_NNS of_IN ACV_NP (_( Sigma_NP ,_, Zwijndrecht_NP ,_, The_DT Netherlands_NPS )_) ranging_VBG from_IN 0.06_CD to_TO 32_CD mug/ml_NN were_VBD used_VBN ._SENT Plates_NNS were_VBD incubated_VBN at_IN 37C_JJ for_IN 2_CD days_NNS and_CC monitored_VBN for_IN development_NN of_IN CPE_NP ._SENT When_WRB complete_JJ CPE_NN was_VBD reached_VBN in_IN control_NN wells_NNS ,_, 300_CD mul_NN of_IN culture_NN supernatants_NNS was_VBD collected_VBN ,_, cleared_VBN by_IN centrifugation_NN (_( 1,100_CD x_SYM g_NN ,_, 1_CD min_NN ,_, 4C_NP )_) ,_, and_CC examined_VBD in_IN real-time_JJ PCR_NP or_CC stored_VBN at_IN -70C_NN until_IN assayed_VBN ._SENT Reference_NN ACV-susceptible_NP (_( KOS_NP )_) and_CC ACV-resistant_NP (_( AraAr8_NP )_) strains_NNS were_VBD included_VBN as_IN controls_NNS in_IN each_DT PCR_NP assay_NN ._SENT The_DT IC50_NP was_VBD used_VBN to_TO express_VB virus_NN drug_NN susceptibility_NN and_CC was_VBD defined_VBN as_IN the_DT concentration_NN of_IN antiviral_JJ drug_NN that_WDT reduced_VBD the_DT number_NN of_IN DNA_NN copies_NNS by_IN 50_CD %_NN relative_JJ to_TO the_DT no-drug_NN virus_NN control_NN ._SENT PRA_NP ._SENT |_SYM The_DT PRA_NP for_IN drug_NN susceptibility_NN determination_NN was_VBD performed_VBN as_IN previously_RB described_VBN by_IN Erlich_NP et_FW al._FW with_IN minor_JJ modifications_NNS ,_, using_VBG neutral_JJ red_NN staining_VBG for_IN plaque_NN detection_NN ._SENT Briefly_RB ,_, confluent_JJ Vero_NP cell_NN monolayers_NNS in_IN 24-well_JJ culture_NN plates_NNS were_VBD inoculated_VBN with_IN 40_CD to_TO 60_CD PFU_NN of_IN virus_NN ._SENT After_IN incubation_NN at_IN 37C_JJ for_IN 1_CD h_NN ,_, the_DT viral_JJ inoculum_NN was_VBD replaced_VBN with_IN culture_NN medium_NN containing_VBG various_JJ concentrations_NNS of_IN ACV_NP and_CC 0.5_CD %_NN agar_NN ._SENT The_DT same_JJ ACV_NP concentrations_NNS were_VBD used_VBN as_RB in_IN the_DT real-time_JJ PCR_NP assay_NN ._SENT Each_DT drug_NN concentration_NN was_VBD tested_VBN in_IN quadruplicate_NN ._SENT The_DT plates_NNS were_VBD incubated_VBN at_IN 37C_JJ for_IN 2_CD to_TO 3_CD days_NNS until_IN plaques_NNS were_VBD observed_VBN in_IN the_DT control_NN wells_NNS without_IN the_DT drug_NN ._SENT Subsequently_RB ,_, the_DT monolayers_NNS were_VBD stained_VBN overnight_RB using_VBG a_DT second_JJ overlay_NN medium_NN containing_VBG 0.08_CD %_NN neutral_JJ red_NN in_IN 0.8_CD %_NN agar_NN ._SENT The_DT same_JJ reference_NN control_NN strains_NNS were_VBD used_VBN in_IN each_DT PRA_NP as_RB were_VBD used_VBN in_IN the_DT in_IN real-time_JJ PCR_NP assay_NN ._SENT The_DT IC50_NP was_VBD defined_VBN as_IN the_DT ACV_NP concentration_NN that_WDT reduced_VBD the_DT number_NN of_IN plaques_NNS by_IN 50_CD %_NN compared_VBN to_TO the_DT untreated_JJ control_NN wells_NNS ._SENT Isolates_NNS were_VBD considered_VBN resistant_JJ to_TO ACV_NP at_IN IC50_NP of_IN >=2_JJ mug/ml_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Results_NNS of_IN real-time_JJ PCR_NP assay_NN and_CC PRA_NP were_VBD analyzed_VBN and_CC compared_VBN using_VBG Wilcoxon_NP 's_POS signed_VBN rank_NN test_NN and_CC Spearman_NP 's_POS correlation_NN coefficient_NN ._SENT Our_PP$ goal_NN was_VBD to_TO develop_VB an_DT easy-to-perform_NN assay_NN for_IN HSV_NP antiviral_JJ susceptibility_NN testing_NN ,_, suitable_JJ for_IN implementation_NN into_IN the_DT modern_JJ routine_JJ diagnostic_JJ laboratory_NN ._SENT To_TO determine_VB and_CC optimize_VB its_PP$ characteristics_NNS ,_, several_JJ parameters_NNS of_IN the_DT assay_NN were_VBD studied_VBN in_IN detail_NN ,_, such_JJ as_IN the_DT viral_JJ replication_NN kinetics_NNS ,_, the_DT effect_NN of_IN ACV_NP in_IN culture_NN supernatant_JJ on_IN PCR_NP efficiency_NN ,_, and_CC the_DT effect_NN of_IN MOI_NP and_CC incubation_NN time_NN on_IN drug_NN susceptibility_NN values_NNS ._SENT Once_IN the_DT optimal_JJ format_NN of_IN the_DT assay_NN was_VBD set_VBN ,_, the_DT test_NN was_VBD validated_VBN on_IN a_DT panel_NN of_IN well-characterized_JJ HSV-1_JJ strains_NNS and_CC clinical_JJ isolates_NNS ._SENT The_DT sensitivity_NN of_IN the_DT real-time_JJ TaqMan_NP PCR_NP to_TO detect_VB HSV_NP DNA_NP was_VBD evaluated_VBN by_IN using_VBG serial_JJ dilution_NN of_IN HSV-1_NP DNA_NP extracted_VBD from_IN EM-counted_JJ virus_NN stock_NN (_( McIntyre_NP )_) ._SENT The_DT quantification_NN was_VBD linear_JJ over_IN the_DT range_NN of_IN concentrations_NNS examined_VBD ,_, from_IN at_IN least_JJS 107_CD to_TO 1,000_CD DNA_NN copies_NNS per_IN ml_NN ._SENT Kinetics_NNS of_IN HSV-1_NP DNA_NP replication_NN ._SENT |_SYM Complete_JJ CPE_NN was_VBD observed_VBN at_IN 36_CD ,_, 48_CD ,_, and_CC 60_CD h_NN after_IN infection_NN for_IN the_DT cultures_NNS infected_VBN at_IN an_DT MOI_NP of_IN 0.1_CD ,_, 0.01_CD ,_, and_CC 0.001_CD PFU/cell_NNS ,_, respectively_RB ._SENT This_DT corresponded_VBD to_TO an_DT HSV-1_JJ DNA_NN yield_NN in_IN the_DT culture_NN supernatant_JJ of_IN approximately_RB 9_CD log10_NN copies/ml_NN ._SENT Culture_NN wells_NNS showing_VBG less_JJR than_IN 30_CD %_NN CPE_NN were_VBD found_VBN to_TO have_VB DNA_NN levels_NNS at_IN the_DT detection_NN limit_NN of_IN the_DT real-time_JJ PCR_NP assay_NN ._SENT Effect_NN of_IN ACV_NP in_IN culture_NN supernatant_JJ on_IN performance_NN of_IN real-time_JJ PCR_NP ._SENT |_SYM Using_VBG a_DT viral_JJ culture_NN supernatant_JJ directly_RB in_IN a_DT PCR_NP analysis_NN may_MD introduce_VB inhibitory_JJ substances_NNS in_IN the_DT PCR_NP ._SENT Particularly_RB the_DT presence_NN of_IN ACV_NP ,_, which_WDT is_VBZ a_DT DNA_NN polymerase_NN inhibitor_NN ,_, in_IN culture_NN supernatants_NNS could_MD inhibit_VB the_DT PCR_NP ._SENT The_DT presence_NN of_IN ACV_NP at_IN 48_CD mug/ml_NN in_IN the_DT cell_NN culture_NN supernatants_NNS decreased_VBD the_DT yield_NN of_IN amplified_VBN products_NNS approximately_RB sixfold_RB ._SENT The_DT inhibitory_JJ effect_NN of_IN ACV_NP was_VBD completely_RB overcome_VBN by_IN diluting_VBG the_DT cell_NN culture_NN supernatant_JJ 100-fold_NN in_IN water_NN prior_RB to_TO PCR_NP ,_, which_WDT was_VBD routinely_RB done_VBN in_IN later_JJR experiments_NNS ._SENT Effect_NN of_IN MOI_NP and_CC incubation_NN time_NN on_IN IC50_NP ._SENT |_SYM The_DT IC50s_NP of_IN ACV_NP in_IN the_DT TaqMan_NP PCR_NP assay_NN at_IN different_JJ MOIs_NN and_CC incubation_NN times_NNS varied_VBN between_IN 0.16_CD and_CC 0.61_CD mug/ml_NN ._SENT Only_RB a_DT slight_JJ increase_NN in_IN IC50s_NP at_IN higher_JJR MOIs_NP was_VBD observed_VBN at_IN each_DT time_NN point_NN ._SENT At_IN 24_CD ,_, 48_CD ,_, and_CC 72_CD h_NN of_IN incubation_NN ,_, respectively_RB ,_, a_DT maximum_JJ 1.8-_CD ,_, 3.2-_CD ,_, and_CC 2.1-fold_JJ difference_NN in_IN IC50_NP was_VBD observed_VBN among_IN the_DT cultures_NNS infected_VBN with_IN a_DT large_JJ range_NN of_IN MOIs_NP from_IN 0.001_CD to_TO 0.5_CD PFU/cell_NN ._SENT For_IN each_DT MOI_NP an_DT increase_NN in_IN IC50_NP with_IN incubation_NN time_NN was_VBD observed_VBN ._SENT The_DT IC50s_NP detected_VBD at_IN 48_CD and_CC 72_CD h_NN were_VBD on_IN average_JJ 2-_CD and_CC 2.4-fold_JJ higher_JJR than_IN those_DT determined_VBN at_IN 24_CD h_NN after_IN infection_NN ._SENT The_DT IC50_NP results_NNS were_VBD comparable_JJ at_IN each_DT MOI_NP regardless_RB of_IN incubation_NN time_NN as_RB long_RB as_IN the_DT susceptibility_NN was_VBD determined_VBN when_WRB the_DT CPE_NN in_IN the_DT virus_NN control_NN was_VBD between_IN 50_CD and_CC <100_JJ %_NN ._SENT The_DT same_JJ findings_NNS were_VBD obtained_VBN for_IN drug-resistant_JJ viruses_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Based_VBN on_IN these_DT results_NNS ,_, an_DT incubation_NN time_NN of_IN 48_CD h_NN and_CC an_DT MOI_NP of_IN 0.01_CD PFU/cell_NP were_VBD subsequently_RB selected_VBN for_IN routine_JJ use_NN ._SENT Antiviral_JJ susceptibility_NN testing_NN using_VBG real-time_JJ PCR_NP assay_NN ._SENT |_SYM The_DT real-time_JJ PCR-based_JJ HSV-1_JJ drug_NN susceptibility_NN assay_NN was_VBD evaluated_VBN in_IN parallel_NN to_TO PRA_NP in_IN a_DT pilot_NN study_NN of_IN nine_CD well-characterized_JJ ACV-sensitive_JJ and_CC resistant_JJ laboratory_NN strains_NNS and_CC six_CD clinical_JJ isolates_NNS ._SENT ACV_NP IC50s_NP determined_VBD by_IN real-time_JJ PCR_NP assay_NN correlated_VBD well_RB with_IN those_DT from_IN PRA_NP (_( r_NN =_SYM 0.86_CD ;_: P_NN <_SYM 0.0001_CD )_) ._SENT In_IN addition_NN ,_, the_DT observed_JJ fold_NN differences_NNS in_IN drug_NN susceptibility_NN between_IN the_DT reference_NN strain_NN KOS_NP and_CC each_DT of_IN the_DT tested_VBN strains_NNS were_VBD highly_RB comparable_JJ between_IN the_DT two_CD assays_NNS (_( r_LS =_SYM 0.99_CD ;_: P_NN <_SYM 0.0001_CD )_) ._SENT The_DT absolute_JJ IC50s_NNS determined_VBN by_IN the_DT real-time_JJ PCR_NP assay_NN were_VBD significantly_RB lower_JJR (_( P_NN <_SYM 0.0001_CD )_) than_IN those_DT from_IN PRA_NP for_IN all_DT ACV-sensitive_JJ and_CC resistant_JJ laboratory_NN strains_NNS and_CC clinical_JJ isolates_NNS ._SENT The_DT average_JJ difference_NN in_IN IC50s_NP was_VBD 7.7-fold_JJ (_( range_NN ,_, 4.1-_CD to_TO 15.0-fold_NN )_) between_IN the_DT two_CD assays_NNS ._SENT Reproducibility_NN ._SENT |_SYM The_DT reproducibility_NN of_IN the_DT cycle_NN threshold_NN (_( Ct_NP )_) values_NNS used_VBN for_IN IC50_NP calculation_NN was_VBD assessed_VBN on_IN two_CD aliquots_NNS of_IN the_DT same_JJ supernatant_JJ samples_NNS collected_VBN from_IN drug_NN treated_VBN and_CC drug_NN control_NN wells_NNS during_IN ACV_NP susceptibility_NN testing_NN of_IN three_CD random_JJ isolates_NNS ._SENT The_DT mean_JJ intra-assay_NN coefficient_NN of_IN variation_NN calculated_VBN from_IN replicate_JJ Ct_NP values_NNS was_VBD 0.71_CD %_NN (_( range_NN ,_, 0.07_CD to_TO 1.8_CD %_NN )_) ,_, indicating_VBG a_DT high_JJ level_NN of_IN reproducibility_NN ._SENT To_TO assess_VB the_DT interexperimental_JJ variability_NN ,_, the_DT IC50_NP of_IN the_DT HSV-1_NP strain_NN KOS_NP was_VBD determined_VBN in_IN seven_CD repeated_JJ experiments_NNS ._SENT This_DT resulted_VBD in_IN a_DT mean_JJ IC50_NN of_IN 0.15_CD mug/ml_NN (_( range_NN ,_, 0.10_CD to_TO 0.25_CD mug/ml_NN ;_: standard_JJ deviation_NN =_SYM 0.06_CD mug/ml_NN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM Time_NP course_NN of_IN changes_NNS in_IN the_DT yield_NN of_IN HSV-1_NP DNA_NP after_IN infection_NN at_IN different_JJ MOIs_NP (_( PFU/cell_NP )_) ._SENT Time_NN course_NN of_IN changes_NNS in_IN the_DT yield_NN of_IN HSV-1_NP DNA_NP after_IN infection_NN at_IN different_JJ MOIs_NP (_( PFU/cell_NP )_) ._SENT The_DT DNA_NP levels_NNS were_VBD measured_VBN in_IN culture_NN supernatants_NNS by_IN real-time_JJ PCR_NP ._SENT The_DT percent_NN values_NNS represent_VBP the_DT percent_NN CPE_NN observed_VBD in_IN the_DT wells_NNS and_CC are_VBP indicated_VBN in_IN the_DT graph_NN until_IN the_DT first_JJ time_NN point_NN that_IN a_DT 100_CD %_NN CPE_NN was_VBD reached_VBN for_IN each_DT MOI_NP ._SENT FIG._NN 2_CD ._SENT |_SYM Fold_NN differences_NNS in_IN susceptibility_NN (_( IC50_NP )_) between_IN the_DT reference_NN strain_NN KOS_NP and_CC tested_VBN strains_NNS as_IN determined_VBN by_IN real-time_JJ PCR_NP assay_NN and_CC PRA_NP (_( r_NN =_SYM 0_CD ._SENT Fold_NN differences_NNS in_IN susceptibility_NN (_( IC50_NP )_) between_IN the_DT reference_NN strain_NN KOS_NP and_CC tested_VBN strains_NNS as_IN determined_VBN by_IN real-time_JJ PCR_NP assay_NN and_CC PRA_NP (_( r_NN =_SYM 0.99_CD )_) ._SENT The_DT trend_NN line_NN is_VBZ aligned_VBN with_IN the_DT correlation_NN coefficient_NN 1.0_CD ._SENT TABLE_NN 1_CD |_SYM Effect_NN of_IN MOI_NP and_CC incubation_NN time_NN on_IN ACV_NP IC50_NP in_IN Vero_NP cells_NNS measured_VBN by_IN real-time_JJ PCR_NP assay_NN (_( HSV-1_NP Mclntyre_NP )_) TABLE_NP 2_CD |_SYM ACV_NP IC50s_NP for_IN HSV-1_NP strains_NNS determined_VBN by_IN real-time_JJ PCR_NP assay_NN and_CC plaque_NN reduction_NN assay_VBP The_DT real-time_JJ PCR_NP assay_NN described_VBN here_RB could_MD be_VB the_DT basis_NN for_IN a_DT useful_JJ novel_NN readout_NN system_NN for_IN antiviral_JJ drug_NN susceptibility_NN determination_NN ._SENT The_DT assay_NN developed_VBN and_CC evaluated_VBN for_IN HSV-1_NP may_MD be_VB generally_RB applicable_JJ to_TO other_JJ viruses_NNS ._SENT The_DT assay_NN measures_VBZ inhibition_NN of_IN HSV-1_NP DNA_NP production_NN by_IN quantification_NN of_IN viral_JJ DNA_NN using_VBG the_DT TaqMan_NP technology_NN ,_, whereas_IN in_IN classical_JJ PRA_NP the_DT reduction_NN of_IN numbers_NNS of_IN virus_NN induced_VBN plaques_NNS is_VBZ used_VBN to_TO determine_VB the_DT antiviral_JJ effect_NN of_IN the_DT drug_NN ._SENT Thus_RB ,_, both_DT assays_NNS measure_VB the_DT effect_NN of_IN viral_JJ replication_NN ,_, though_IN using_VBG different_JJ read-out_JJ parameters_NNS ._SENT The_DT determination_NN of_IN these_DT different_JJ parameters_NNS may_MD explain_VB the_DT differences_NNS in_IN absolute_JJ IC50s_NNS between_IN the_DT two_CD assays_NNS ._SENT Moreover_RB ,_, PRA_NP does_VBZ not_RB take_VB into_IN account_NN the_DT effect_NN of_IN antiviral_JJ agent_NN on_IN the_DT plaque_NN size_NN ._SENT In_IN PRA_NP the_DT antiviral_JJ effect_NN of_IN the_DT drug_NN is_VBZ often_RB manifested_VBN as_IN a_DT decrease_NN in_IN plaque_NN size_NN without_IN complete_JJ prevention_NN of_IN plaque_NN formation_NN ._SENT Smaller_JJR plaques_NNS in_IN drug-treated_JJ wells_NNS consist_VBP of_IN lower_JJR numbers_NNS of_IN virus-infected_JJ cells_NNS but_CC are_VBP counted_VBN equally_RB to_TO plaques_NNS of_IN normal_JJ size_NN in_IN control_NN wells_NNS ,_, which_WDT leads_VBZ to_TO overestimation_NN of_IN viral_JJ susceptibility_NN ._SENT The_DT real-time_JJ PCR_NP assay_NN ,_, however_RB ,_, measures_VBZ the_DT true_JJ reduction_NN of_IN viral_JJ DNA_NN production_NN ,_, which_WDT is_VBZ the_DT basic_JJ mechanism_NN underlying_VBG the_DT antiviral_JJ effect_NN of_IN the_DT drug_NN ._SENT As_IN such_JJ ,_, the_DT real-time_JJ PCR_NP assay_NN may_MD give_VB more_RBR accurate_JJ estimation_NN of_IN the_DT effect_NN of_IN the_DT drug_NN on_IN viral_JJ replication_NN ._SENT In_IN the_DT real-time_JJ PCR-based_JJ HSV-1_JJ drug_NN susceptibility_NN assay_NN ,_, the_DT effect_NN of_IN the_DT MOI_NP on_IN the_DT ACV_NP susceptibility_NN was_VBD limited_VBN ,_, which_WDT was_VBD demonstrated_VBN by_IN only_JJ small_JJ differences_NNS in_IN IC50_NP among_IN the_DT cultures_NNS infected_VBN with_IN a_DT large_JJ range_NN of_IN MOIs_NP (_( 500-fold_NN difference_NN )_) ._SENT The_DT effect_NN of_IN the_DT MOI_NP was_VBD small_JJ as_RB long_RB as_IN the_DT virus_NN had_VBD not_RB infected_VBN all_PDT the_DT cells_NNS ._SENT An_DT incubation_NN time_NN of_IN 48_CD h_NN was_VBD routinely_RB used_VBN in_IN our_PP$ assay_NN ._SENT However_RB ,_, considering_VBG the_DT reported_VBN differences_NNS in_IN growth_NN rates_NNS of_IN clinical_JJ isolates_NNS ,_, it_PP cannot_MD be_VB excluded_VBN that_IN longer_JJR incubation_NN times_NNS will_MD be_VB needed_VBN for_IN particular_JJ isolates_NNS to_TO reach_VB sufficient_JJ amount_NN of_IN CPE_NP (_( 50_CD %_NN )_) required_VBN for_IN reproducible_JJ real-time_JJ PCR_NP analysis_NN ._SENT Therefore_RB ,_, rather_RB than_IN harvesting_VBG the_DT virus_NN at_IN a_DT fixed_VBN reading_NN time_NN ,_, we_PP would_MD recommend_VB monitoring_VBG CPE_NN and_CC subsequent_JJ susceptibility_NN testing_NN at_IN CPE_NN levels_NNS ranging_VBG from_IN 50_CD %_NN to_TO <100_JJ %_NN ._SENT The_DT real-time_JJ PCR_NP assay_NN was_VBD evaluated_VBN by_IN testing_VBG 15_CD HSV-1_JJ strains_NNS for_IN ACV_NP susceptibility_NN and_CC by_IN comparing_VBG the_DT results_NNS with_IN those_DT from_IN the_DT conventional_JJ PRA_NP ._SENT The_DT test_NN showed_VBD good_JJ correlation_NN with_IN PRA_NP on_IN IC50s_NP and_CC also_RB the_DT fold_NN differences_NNS in_IN susceptibility_NN between_IN the_DT reference_NN sensitive_JJ and_CC tested_VBN strains_NNS highly_RB correlated_VBN ._SENT Based_VBN on_IN the_DT range_NN of_IN IC50s_NNS obtained_VBN for_IN sensitive_JJ HSV_NP strains_NNS and_CC clinical_JJ isolates_NNS ,_, a_DT cutoff_NN value_NN of_IN 0.3_CD mug/ml_NN for_IN ACV_NP was_VBD considered_VBN as_IN a_DT discriminative_JJ concentration_NN for_IN sensitive_JJ and_CC resistant_JJ strains_NNS in_IN the_DT real-time_JJ PCR_NP assay_NN ._SENT For_IN a_DT better_JJR and_CC more_JJR accurate_JJ definition_NN of_IN the_DT in_IN vitro_NP resistance_NN threshold_NN of_IN this_DT assay_NN ,_, a_DT larger_JJR number_NN of_IN clinical_JJ isolates_NNS needs_VBZ to_TO be_VB analyzed_VBN ._SENT Nevertheless_RB ,_, as_IN the_DT threshold_NN values_VBZ defining_VBG sensitive_JJ and_CC resistant_JJ virus_NN can_MD differ_VB depending_VBG on_IN the_DT assay_NN utilized_VBD ,_, the_DT fold-differences_NNS in_IN drug_NN susceptibility_NN compared_VBN to_TO a_DT reference_NN strain_NN may_MD provide_VB more_RBR relevant_JJ information_NN for_IN comparing_VBG results_NNS generated_VBN with_IN different_JJ drug_NN susceptibility_NN assays_NNS ._SENT The_DT real-time_JJ PCR_NP assay_NN described_VBD here_RB allows_VBZ the_DT rapid_JJ determination_NN of_IN the_DT ACV_NP susceptibility_NN of_IN HSV_NP strains_NNS ._SENT The_DT test_NN was_VBD only_RB mildly_RB affected_VBN by_IN variation_NN in_IN the_DT MOI_NP ,_, while_IN quite_RB accurate_JJ titration_NN of_IN the_DT clinical_JJ isolate_NN is_VBZ required_VBN for_IN PRA_NP ._SENT The_DT real-time_JJ PCR_NP assay_NN has_VBZ an_DT objective_JJ readout_NN and_CC a_DT good_JJ reproducibility_NN ,_, furthermore_RB it_PP is_VBZ more_RBR rapid_JJ and_CC easier_JJR to_TO perform_VB than_IN the_DT PRA_NP ._SENT Full_JJ susceptibility_NN testing_NN results_NNS from_IN the_DT real-time_JJ PCR_NP assay_NN were_VBD obtained_VBN within_IN 3_CD days_NNS ,_, in_IN contrast_NN to_TO the_DT usual_JJ 4_CD to_TO 6_CD days_NNS required_VBN for_IN PRA_NP ._SENT This_DT is_VBZ a_DT considerable_JJ improvement_NN and_CC in_IN combination_NN with_IN the_DT technology_NN already_RB available_JJ in_IN many_JJ routine_JJ diagnostic_JJ laboratories_NNS may_MD render_VB it_PP a_DT useful_JJ test_NN for_IN the_DT clinical_JJ virology_NN laboratory_NN ._SENT At_IN present_JJ ,_, real-time_JJ PCR-based_JJ assays_NNS are_VBP increasingly_RB implemented_VBN into_IN diagnostic_JJ clinical_JJ virology_NN because_IN of_IN their_PP$ high_JJ sensitivity_NN ,_, high_JJ throughput_NN ,_, and_CC ease_VB of_IN use_NN format_NN ._SENT The_DT real-time_JJ PCR_NP assay_NN described_VBD here_RB uses_VBZ the_DT same_JJ PCR_NP components_NNS and_CC is_VBZ performed_VBN under_IN the_DT same_JJ standard_JJ amplification_NN conditions_NNS that_WDT are_VBP routinely_RB used_VBN for_IN detection_NN of_IN HSV_NP in_IN clinical_JJ specimens_NNS ._SENT Thus_RB ,_, the_DT assay_NN fits_VBZ in_IN well_RB with_IN methods_NNS already_RB available_JJ in_IN the_DT clinical_JJ virology_NN laboratory_NN and_CC as_RB such_JJ it_PP could_MD be_VB easily_RB implemented_VBN in_IN many_JJ clinical_JJ laboratories_NNS ._SENT In_IN house_NN availability_NN of_IN antiviral_JJ susceptibility_NN testing_NN would_MD enable_VB physicians_NNS to_TO obtain_VB results_NNS on_IN drug_NN susceptibility_NN in_IN a_DT clinically_RB useful_JJ time_NN frame_NN and_CC may_MD help_VB explaining_VBG therapeutic_JJ failure_NN in_IN patients_NNS not_RB responding_VBG adequately_RB to_TO treatment_NN ._SENT In_IN conclusion_NN ,_, we_PP demonstrated_VBD the_DT real-time_JJ PCR_NP assay_NN as_IN a_DT suitable_JJ method_NN for_IN the_DT determination_NN of_IN antiviral_JJ drug_NN susceptibility_NN for_IN HSV-1_NP ._SENT Application_NN of_IN the_DT assay_NN for_IN clinical_JJ practice_NN needs_VBZ to_TO be_VB further_RBR evaluated_VBN ._SENT 